Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 393 - 400 of 12092 results
Sooner the Better: Employers in Canada Should Really Review Their Termination of Employment Clauses
January 29, 2025| Blog| Viewpoint
Employer Win on FLSA Exemption Issue – Heightened Pleading Standard Rejected by High Court
January 28, 2025| Blog| Viewpoint
Will Extending Tax Cuts Cost Retirement Savers?
January 28, 2025| News
Remote Access to Anti-Addiction Meds Unclear under Trump
January 28, 2025| News
Mintz on Air: Predictions and Practical Policies - Employee Handbooks: Do You or Don't You?
January 27, 2025| Podcast| Viewpoint
How Directors Can Navigate the DEI Divide
January 27, 2025| News
President Trump Starts First Week with AI Executive Orders and Investments — AI: The Washington Report
January 24, 2025| Article| Viewpoint
USPTO Issues Artificial Intelligence Strategy
January 24, 2025| Article| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|